IncyteINCY

NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation

Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.

Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.

Key metrics

Market cap

$24.4B

Price

$127.98

Today

+0.1%

Return YTD

+29.4%

Return 1Y

+47.7%

P/E

15.1

P/S

4.2

P/B

3.8

Data as of 2026-08-25 · updates daily after U.S. close

Theme exposure

Oncology biotechOncologyInflammationDermatology

In the value chain

Products & services

Jakafi (myelofibrosis)
Opzelura (dermatology)
Oncology pipeline

Competitors

Risks

Jakafi concentration
Patent expiry

Supply chain

Supplies →

CencoraCOR

← Suppliers

Charles River LaboratoriesCRL

Full supply chain for INCY →

Same segment: Biotech & innovation

AmgenAMGN Gilead SciencesGILD Vertex PharmaceuticalsVRTX RegeneronREGN BiogenBIIB Alnylam PharmaceuticalsALNY ModernaMRNA United TherapeuticsUTHR

Compare INCY

INCY vs AMGN INCY vs GILD INCY vs VRTX INCY vs REGN INCY vs BIIB INCY vs ALNY

See where Incyte sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →